Multiple drug classes currently in Phase III clinical development for NAFLD/NASH target the diverse pathophysiology associated with metabolic liver disease including fibroblast growth factor analogs, PPAR transcription factors, bile acid receptors, SGLT2 inhibitors (Ala, 2021), GLP-1 receptors and thyroid hormone receptors (Sinakos et al., 2022). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.